In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: No evidence of platelet activation

Blood

Volumn 119, Issue 17, 2012, Pages 4066-4072

  Psaila, Bethan ^a,b   Bussel, James B ^a   Linden, Matthew D ^c   Babula, Bracken ^a   Li, Youfu ^c   Barnard, Marc R ^c,d   Tate, Chinara ^a   Mathur, Kanika ^a   Frelinger, Andrew L ^c,d   Michelson, Alan D ^c,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ELTROMBOPAG; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ADULT; AGED; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE;

EID: 84860324484     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-393900     Document Type: Article

References (35)

1. Stasi R, Newland AC. ITP: a historical perspective. Br J Haematol. 2011; 153(4):437-450.
2. CukerA, Cines DB. Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2010:377-384.
3. Kuter DJ. New thrombopoietic growth factors. Blood. 2007; 109(11):4607-4616. (Pubitemid 46827750)
4. Newland A. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura. Semin Hematol. 2007; 44(4 suppl 5):35-45.
5. Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011; 365(8):734-741.
6. Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009; 27(2):424-430.
7. Karpatkin S. Heterogeneity of human platelets, II: functional evidence suggestive of young and old platelets. J Clin Invest. 1969; 48:1083-1086.
8. Karpatkin S. Heterogeneity of human platelets. VI. Correlation of platelet function with platelet volume. Blood. 1978; 51(2):307-316.
9. Panzer S, Hocker L, Rieger M, et al. Agonist-inducible platelet activation in chronic idiopathic autoimmune thrombocytopenia. Eur J Haematol. 2007; 79(3):198-204. (Pubitemid 47231164)
10. Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood. 1995; 85(2):391-401.
11. Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryo cyte growth and development factor on platelet production and function in nonhuman primates. Blood. 1996; 88(2):511-521. (Pubitemid 26240383)
12. Peng J, Friese P, Wolf RF, et al. Relative reactivity of platelets from thrombopoietin- and interleukin-6-treated dogs. Blood. 1996; 87(10):4158-4163.
13. Harker LA. Platelets in thrombotic disorders: quantitative and qualitative platelet disorders predisposing to arterial thrombosis. Semin Hematol. 1998; 35(3):241-252. (Pubitemid 28337233)
14. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007; 109(11):4739-4741. (Pubitemid 46827766)
15. Afdhal N, Giannini E, Tayyab GN, et al. Eltrombopag in chronic liver disease patients with thrombocytopenia undergoing an elective invasive procedure: Results from ELEVATE, a randomised clinical trial. European Association for the Study of Liver (Oral Presentation, Annual Meeting). April 2010.
16. Michelson AD. Flow cytometry: a clinical test of platelet function. Blood. 1996; 87(12):4925-4936. (Pubitemid 26189833)
17. Michelson A, Linden MD, Barnard MR, Furman MI, Frelinger AL. Flow cytometry. In: Michelson A, ed. Platelets. San Diego, CA: Elsevier/Academic Press; 2007:545-563.
18. Han Y, Nurden A, Combrie R, Pasquet JM. Redistribution of glycoprotein Ib within platelets in response to protease-activated receptors 1 and 4: roles of cytoskeleton and calcium. J Thromb Haemost. 2003; 1(10):2206-2215.
19. Michelson AD, Ellis PA, Barnard MR, Matic GB, Viles AF, Kestin AS. Down-regulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or an in vivo wound. Blood. 1991; 77(4): 770-779.
20. LaRosa CA, Rohrer MJ, Benoit SE, Barnard MR, Michelson AD. Neutrophil cathepsin G modulates the platelet surface expression of the glycoprotein (GP) Ib-IX complex by proteolysis of the von Willebrand factor binding site on GPIb alpha and by a cytoskeletal-mediated redistribution of the remainder of the complex. Blood. 1994; 84(1):158-168.
21. Bussel JB, Psaila B, Saleh M, et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura [abstract]. Blood (ASH Annual Meeting Abstracts). 2008:3431a.
22. Saleh M, Cheng G, Bussel JB, et al. EXTEND study update: safety and efficacy of eltrombopag in adults with chronic immune thrombocytopenia (ITP) from June 2006 to February 2010 [abstract]. Blood (ASH Annual Meeting Abstracts). 2010: 67a.
23. Cheng G, Saleh MN, Marcher C, et al. Eltrom-bopag for management of chronic immune throm-bocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377(9763):393-402.
24. Ruisi MM, Psaila B, Ward MJ, Villarica G, Bussel JB. Stability of measurement of the immature platelet fraction. Am J Hematol. 2010; 85(8):622-624.
25. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem. 1985; 260(20):11107-11114. (Pubitemid 16253272)
26. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocyto-penic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373(9664): 641-648.
27. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008; 371(9610): 395-403. (Pubitemid 351181334)
28. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007; 357(22):2237-2247. (Pubitemid 350190754)
29. Severinsen MT, Engebjerg MC, Farkas DK, et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2011; 152(3):360-362.
30. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004; 104(4):956-960. (Pubitemid 39038013)
31. Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica. 2010; 95(7):1167-1175.
32. Michelson AD, Adelman B, Barnard MR, Carroll E, Handin RI. Platelet storage results in a redistribution of glycoprotein Ib molecules. Evidence for a large intraplatelet pool of glycoprotein Ib. J Clin Invest. 1988; 81(6):1734-1740.
33. Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol. 2009; 37(9):1030-1037.
34. Haselboeck J, Pabinger I, Ay C, Koder S, Panzer S. Platelet activation and function during eltrombopag treatment in immune thrombocytopenia. Ann Hematol. 2012; 91(1):109-113.
35. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010; 363(20): 1889-1899.